ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / WOK / earnings
NVNO (33) SNOA (34) XAIR (30) TNON (30) ⌘ Pro Terminal →

WORK Medical Technology Group LTD (Class A) (WOK) Next Earnings Date & Expected ±12.5% Move

$1.00 -9.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.98

WORK Medical Technology Group LTD (Class A) (WOK) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →
ROARABLE D • SELL / AVOID Cap $4.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WOK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $1.00 (-9.09% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, WOK ranks #257 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WOK compare to NVNO and SNOA in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while NVNO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WOK?
▼

Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $13.9M in revenue, -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.98 (-1.83%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 35.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (16)Whales (3)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3% Base Target
$87780 Bull$1 Base$1 Bear
📬 FREE WOK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WOK)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY WOK SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 35.3% FCF Margin ($4.9M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$1.39-17.3% Next Q
Q2 (-2Q)
56
Grade C$1.15+1.7% Next Q
Q3 (-1Q)
54
Grade C-$1.17-14.5% Next Q
Current
51
Grade D$1.00-1.3% Hist 90D α
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a WOK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While WOK currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.66) and Max Pain ($1.05) forces dealer call-delta covering toward $87,780.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WOK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “WOK Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 29, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.13 Expected Swing
$1.00 (-12.5%)Spot $1.00$1.13 (+12.5%)
MODEL EARNINGS SETUP GAUGE

WOK Quantitative Pre-Earnings Setup: 51/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (51/100)Model Risk Weight (49/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-09-30$13.9M-$1.1M$4.9M52%
FY 20242024-09-30$0-$3.5M-$11.5M52%
FY 20232023-09-30$0$112.0K$2.2M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WOK)

  • ✓Walkthrough of WOK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
WOK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -99.27%▲ RESISTANCE BREAKOUT
2026-11-03O $1.10H $1.10L $1.00C $1.00VOL 61.2K
RES: $0.82SUP: $0.98SMA50: $1.66SMA200: $60.94
$216,084.8$157,520.1$98,955.3$40,390.5$-18,174.28RES $0.82SUP $0.98$1.002026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WOK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WOK Butterfly Map → + Track WOK →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WOK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WOK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WOK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WOK)

Health Care Rank #257 of 1016 ⚔️ NVNO vs WOK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WOK vs. NVNO, SNOA, XAIR, TNON)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, WORK Medical Technology Group LTD (Class A) (WOK) ranks #257 by composite RQD confidence (51/100, grade D) and #954 by equity capitalization ($4.5M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while NVNO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. WOK currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
WOK ACTIVE
WORK Medical Technology Group LTD (Class A)
D 51/100 — — — -9.09% $4.5M Benchmark Subject
NVNO
enVVeno Medical Corporation
E 33/100 — — -35.0% -4.13% $4.7M /nvno-vs-wok →
SNOA
Sonoma Pharmaceuticals Inc.
E 34/100 — 38.0% -35.0% -8.33% $5.3M /snoa-vs-wok →
XAIR
Beyond Air Inc.
E 30/100 112.1x 3.3% -35.0% -3.03% $3.7M /xair-vs-wok →
TNON
Tenon Medical Inc.
E 30/100 — 59.8% -35.0% -10.48% $5.5M /tnon-vs-wok →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001929783

In its most recent audited fiscal period (FY2025, filed 2025-09-30), WORK Medical Technology Group LTD (Class A) (WOK) reported GAAP revenue of $13.9M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$1.1M, operating cash flow of $6.2M, and free cash flow of $4.9M (+142.9% YoY). On the balance sheet, WOK closed FY2025 with $33.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $13.9M -$1.1M $6.2M $4.9M $33.2M —
FY2024 (FY) 2024-09-30 $0 -$3.5M -$2.2M -$11.5M — —
FY2023 (FY) 2023-09-30 $0 $112.0K $2.2M $2.2M — —

3. WOK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $1.00 (-9.09% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, WOK ranks #257 in composite RQD confidence.

How does WOK compare to NVNO and SNOA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while NVNO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WOK?

Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $13.9M in revenue, -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WOK trading relative to its 50-day, 200-day, and 52-week technical levels?

WOK last traded at $1.00 (-9.09% on volume of 61,191 shares), positioning the stock -39.76% below its 50-day simple moving average ($1.66) and -98.36% below its 200-day simple moving average ($60.94). Across its 52-week range of $1.00 to $83,600.00, WOK sits at the 0.0% percentile with a 14-day RSI of 31.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.13).

WOK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is WOK's next earnings date?

Based on SEC filing cadence, WORK Medical Technology Group LTD (Class A) (WOK)'s next quarterly reporting window is estimated around Dec 29, 2026.

How much is WOK stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for WOK, spanning a range between $1 and $1.13.

Direct Sub-Reports: WOK RQD Cockpit WOK 12M Forecast WOK Earnings & Move WOK Dividends & DRIP WOK Insiders & 13F WOK Whale Options WOK Profit Sankey WOK News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

WOK — WORK Medical Technology Group LTD (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:53:22Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, WOK scores 51 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The score is built from five pillars:

  • Fundamental Cash Engine: 16 / 20. The rating cites ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash yield relative to the share price.
  • Whale 13F Flow: 3 / 20. This pillar, covering institutional accumulation and options positioning, is the weakest in the set, indicating little supportive institutional flow in the source data.
  • Insider Conviction: 9 / 20. This pillar reflects SEC Form 4 and Congressional PTR cluster flow, and scores below midpoint.
  • Macro Regime Fit: 10 / 20. The rating cites Beta of 1.0 and sector sensitivity; the stock carries no reduced market-sensitivity advantage per the source.
  • Forensic Balance Sheet: 13 / 20. The rating cites Altman Z of 2.5, Piotroski F of 4/9, and Debt/Equity of 0.5. These are mid-range readings rather than a clear strength.

Taken together, the rating frames WOK as a name where the cash-generation and institutional-flow signals are weak, with the balance-sheet pillar providing the most support. Tradeoffs for a prospective investor include the very low share price ($1.1), a $4.9M market capitalization, and a 52-week range of $1 - $83600, which the source data presents without further explanation. This is an analytical framing, not personalized advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-09-30)$0.0M$0.0M$-1.1MN/A$4.9MN/AN/A
FY 2024 (filed 2024-09-30)$0.0M$0.0M$-3.5MN/A$-11.5MN/AN/A
FY 2023 (filed 2023-09-30)$0.0M$0.0M$0.1MN/A$2.2MN/AN/A

Per the SEC financials, reported revenue and operating income are $0.0M in each period, and net margin, gross margin, and operating margin are each 0%. Per the market data, ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. Cash and debt balances are N/A in the financials, so the source data does not give a full balance-sheet picture beyond these ratios.

Recent Catalysts & News Wire Analysis

Per the recent news feed, all five items are tagged to WOK with a YELLOW light and a MARKET WIRE impact label:

  • A Yahoo! Finance Canada item, published 1h ago, covering market action, institutional positioning, and fundamental catalysts.
  • A report from siam.in, published 3h ago, headlined as WOK holding flat at $1.11 with traders watching range boundaries.
  • A TradingKey item, published 6h ago, on unusual volume and volume spikes.
  • A Yahoo Finance Australia item, published 9h ago, covering price and history.
  • A TradingKey item, published 12h ago, on 52-week high stocks.

The news items describe market activity and price behavior but do not identify a specific fundamental catalyst. Risk watch items per the data include the flat price near $1.11, the reported volume of 12674, and the −4.35% change. Proprietary signals per the Butterfly Supply-Chain Graph: none.

Open Questions

  • What products or services does the company sell, and what is its revenue source given reported revenue of $0.0M in each period?
  • What explains the 52-week range of $1 - $83600, and what corporate or capital-structure events are behind it?
  • What are the cash and debt balances, given that these fields are N/A in the financials?
  • What is the basis for the reported FCF of $4.9M in FY 2025 alongside net income of $-1.1M, and what drove the swing from $-11.5M in FY 2024?
  • Who are the company's institutional holders and insiders, and what is the current trading activity behind the volume of 12674?

WOK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for WORK Medical Technology Group LTD (Class A) (WOK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WOK Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WOK Bull vs. Bear Conversation Board — What's Your Call at $1.00?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WOK 🐻 50% BEARISH CONVICTION
1. Pick Your Side on WOK:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.19 (+8.2%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is WOK (D • RQD 51/100) a Buy at $1.10?

Welcome to the WOK (WORK Medical Technology Group LTD (Class A)) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.87 (-20.9%)
Spot @ $1.10

Pump the brakes on WOK — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on WOK, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless WORK Medical Technology Group LTD (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.36 (+23.6%)
Spot @ $1.10

WOK cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on WOK, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $1.10 (52-wk range $1.00 - $83600.00), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%